title: A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker.
abstract: Recent studies with nivolumab (a monoclonal antibody against programmed cell death 1 [PD-1] receptor) have shown promise non-small-cell lung cancer (NSCLC) treatment.
  
  
  
  To review available clinical trials data in order to assess nivolumab efficacy and the role of tumoral PDL-1 expression as a biomarker.
  
  
  
  Nine eligible studies included 2102 patients. In the second line setting, nivolumab achieved a 1-year survival rate of 41%; and in the first line, a 1-year survival rate of 76%. For those with PD-L1 expression <1%, nivolumab showed a trend for improved survival compared with docetaxel.
  
  
  
  The available data reinforce nivolumab activity against NSCLC in first-line or subsequent lines. Although PD-L1 expression is related to greater response, PD-L1 negative patients had also some benefit.
authors.affiliation: Division of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil.
authors.forename: Pedro N
authors.initials: PN
authors.lastname: Aguiar
authors.affiliation: Division of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil.
authors.forename: Ilka Lopes
authors.initials: IL
authors.lastname: Santoro
authors.affiliation: Division of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil.
authors.forename: Hakaru
authors.initials: H
authors.lastname: Tadokoro
authors.affiliation: Department of Medical Oncology, Johns Hopkins University, Baltimore, MD 21218, USA.
authors.forename: Gilberto
authors.initials: G
authors.lastname: de Lima Lopes
authors.affiliation: Division of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil.
authors.forename: Bruno Andraus
authors.initials: BA
authors.lastname: Filardi
authors.affiliation: Department of Population Studies, Abel Salazar Biomedical Institute, University of Porto, Porto, Portugal.
authors.forename: Pedro
authors.initials: P
authors.lastname: Oliveira
authors.affiliation: Division of Oncology, Department of Biomedical Sciences & Medicine, University of Algarve, Faro, Portugal.
authors.forename: Pedro
authors.initials: P
authors.lastname: Castelo-Branco
authors.affiliation: Department of Medical Oncology, University of Athens Medical School, Athens, Greece.
authors.forename: Giannis
authors.initials: G
authors.lastname: Mountzios
authors.affiliation: Division of Oncology, Department of Biomedical Sciences & Medicine, University of Algarve, Faro, Portugal.|Department of Medicine, Faculty of Medicine, University of Porto, Porto, Portugal.|Research Center, Cearense School of Oncology, Instituto do Câncer do Ceará, Fortaleza, CE, Brazil.
authors.forename: Ramon Andrade
authors.initials: RA
authors.lastname: de Mello
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D060890:B7-H1 Antigen / Q000235:genetics / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D000077143:Docetaxel; D006801:Humans; D000077594:Nivolumab; D011237:Predictive Value of Tests; D011379:Prognosis; D016019:Survival Analysis; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; D014408:Biomarkers, Tumor; D043823:Taxoids; D000077143:Docetaxel; D000077594:Nivolumab
keywords: lung cancer; meta-analysis; nivolumab